Zobrazeno 1 - 10
of 216
pro vyhledávání: '"Amod A, Sarnaik"'
Autor:
Kate E. Beekman, Danielle K. DePalo, Lily M. Parker, Kelly M. Elleson, John E. Mullinax, Amod A. Sarnaik, Vernon K. Sondak, Jonathan S. Zager
Publikováno v:
Cancer Control, Vol 31 (2024)
Background Radar-guided localization (RGL) offers a wire-free, nonradioactive surgical guidance method consisting of a small percutaneously-placed radar reflector and handheld probe. This study investigates the feasibility, timing, and outcomes of RG
Externí odkaz:
https://doaj.org/article/09dc533c0fad4b4ab04ed742c27070bd
Autor:
James Larkin, Harriet Kluger, Omid Hamid, Jeffrey Weber, Amod A Sarnaik, Brian Gastman, Jeffrey Chou, John M Kirkwood, Eric Whitman, Martin Wermke, Evidio Domingo-Musibay, Theresa Medina, Sajeve Thomas, Wen Shi, Xiao Wu, Jason A Chesney, Giri Sulur, Friedrich Graf Finckenstein
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/dd15fbf338ed45b1a76ce053944ef9df
Autor:
Joseph Markowitz, Shari Pilon-Thomas, Amod A Sarnaik, Pei-ling Chen, Ahmad A Tarhini, Zeynep Eroglu, Andrew S Brohl, Nikhil I Khushalani, Vernon K Sondak, Youngchul Kim, Michael Shamblott, Christopher W Dukes, Alejandra Chamizo, Marina Bastawrous, Edward Garcia, Ashraf Delhawi, Deanryan BDe Aquino, Patricia Lawman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/9bd031bd3186447cb187adb5c94e6559
Autor:
Shari Pilon-Thomas, Daniel Abate-Daga, Amod A. Sarnaik, James J. Mule, Xiaoqing Yu, Patrick Innamarato, Jamie Blauvelt, Holly Branthoover, Jake Ceccarelli, TJ Langer, MacLean S. Hall, Jamie K. Teer, Sebastian Snedal, Madeline Rodriguez-Valentin, Luz Nagle, Ellen Scott, Ben Schachner, Amy M. Hall, Carolyn J. Rich, Allison D. Richards, Sean J. Yoder, Matthew S. Beatty, Cheryl A. Cox, Jane L. Messina, John E. Mullinax
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 10 (2023)
Background Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) is a promising immunotherapeutic approach for patients with advanced solid tumors. While numerous advances have been made, the contribution of neoantigen-specific CD4+T
Externí odkaz:
https://doaj.org/article/389eec90db77472d949e719312488bf2
Autor:
Kate E. Beekman, BS, Lily M. Parker, BS, Danielle K. DePalo, MD, Kelly M. Elleson, MD, Amod A. Sarnaik, MD, Kenneth Y. Tsai, MD, PhD, Bethany M. Withycombe, PharmD, BCOP, Jonathan S. Zager, MD
Publikováno v:
JAAD Case Reports, Vol 33, Iss , Pp 56-58 (2023)
Externí odkaz:
https://doaj.org/article/cfeaf9dad2e248b5a8bfd973351f2109
Autor:
Erin McClure BS, Michael J Carr MD, MS, Ayushi Patel BS, Syed Mahrukh Hussnain Naqvi MD, MPH, Youngchul Kim PhD, Michael Harrington MD, Wayne Cruse MD, Ricardo J Gonzalez MD, Vernon K Sondak MD, Amod A Sarnaik MD, Jane L Messina MD, Jonathan S Zager MD
Publikováno v:
Cancer Control, Vol 30 (2023)
Background Atypical fibroxanthomas (AFX) are rare malignant cutaneous neoplasms. Unfortunately, limited clinicopathologic and outcomes data on this cancer exists. Objective We report the clinical, pathologic, and treatment characteristics, as well as
Externí odkaz:
https://doaj.org/article/c7abe111593d48f8891c7567835fa5eb
Autor:
Patrick Innamarato, Jennifer Morse, Amy Mackay, Sarah Asby, Matthew Beatty, Jamie Blauvelt, Scott Kidd, John E. Mullinax, Amod A. Sarnaik, Shari Pilon-Thomas
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
Abstract Background Chemotherapy regimens that include the utilization of gemcitabine are the standard of care in pancreatic cancer patients. However, most patients with advanced pancreatic cancer die within the first 2 years after diagnosis, even wh
Externí odkaz:
https://doaj.org/article/32e2ee001c5e4d209c02f66427128c37
Autor:
Kristy K, Broman, Tasha M, Hughes, Brooke C, Bredbeck, James, Sun, Dennis, Kirichenko, Michael J, Carr, Avinash, Sharma, Edmund K, Bartlett, Amanda A G, Nijhuis, John F, Thompson, Tina J, Hieken, Lisa, Kottschade, Jennifer, Downs, David E, Gyorki, Emma, Stahlie, Alexander, van Akkooi, David W, Ollila, Kristin, O'shea, Yun, Song, Giorgos, Karakousis, Marc, Moncrieff, Jenny, Nobes, John, Vetto, Dale, Han, Meghan, Hotz, Jeffrey M, Farma, Jeremiah L, Deneve, Martin D, Fleming, Matthew, Perez, Kirsten, Baecher, Michael, Lowe, Roger Olofsson, Bagge, Jan, Mattsson, Ann Y, Lee, Russell S, Berman, Harvey, Chai, Hidde M, Kroon, Juri, Teras, Roland M, Teras, Norma E, Farrow, Georgia M, Beasley, Jane Yuet Ching, Hui, Lukas, Been, Schelto, Kruijff, Brandy, Sinco, Amod A, Sarnaik, Vernon K, Sondak, Jonathan S, Zager, Lesly A, Dossett
Publikováno v:
Annals of Surgery. 277(5):1106-1115
Objective: The aim of this study was to determine overall trends and center-level variation in utilization of completion lymph node dissection (CLND) and adjuvant systemic therapy for sentinel lymph node (SLN)-positive melanoma. Summary Background Da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8148e9aa82b592a8d19b23b3d4d03d60
https://doi.org/10.1097/SLA.0000000000005370
https://doi.org/10.1097/SLA.0000000000005370
Autor:
Ahmet Murat Aydin, Brittany L. Bunch, Matthew Beatty, Ali Hajiran, Jasreman Dhillon, Amod A. Sarnaik, Shari Pilon-Thomas, Michael A. Poch
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Tumor infiltrating lymphocytes (TIL) therapy was shown to provide durable objective response in patients with metastatic melanoma. As a fundamental first step to bring TIL therapy to clinical use, identification of patients whose tumors yield optimal
Externí odkaz:
https://doaj.org/article/90a50ca283db47c89748bd948ad255ee
Autor:
MacLean S. Hall, John E. Mullinax, Cheryl A. Cox, Amy M. Hall, Matthew S. Beatty, Jamie Blauvelt, Patrick Innamarato, Luz Nagle, Holly Branthoover, Doris Wiener, Benjamin Schachner, Alberto J. Martinez, Allison D. Richards, Carolyn J. Rich, Marjorie Colón Colón, Michael J. Schell, Jamie K. Teer, Nikhil I. Khushalani, Jeffrey S. Weber, James J. Mulé, Vernon K. Sondak, Shari Pilon-Thomas, Amod A. Sarnaik
Publikováno v:
Clin Cancer Res
Purpose: Metastatic melanoma is a tumor amenable to immunotherapy in part due to the presence of antigen-specific tumor-infiltrating lymphocytes (TIL). These T cells can be activated and expanded for adoptive cell transfer (ACT), which has resulted i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::079ac7f397d9831674a16a2454385b10
https://doi.org/10.1158/1078-0432.ccr-22-2103
https://doi.org/10.1158/1078-0432.ccr-22-2103